4.5 Article

Cardiac arrest and therapeutic hypothermia

期刊

TRENDS IN CARDIOVASCULAR MEDICINE
卷 26, 期 4, 页码 337-344

出版社

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tcm.2015.10.002

关键词

Cardiac arrest; therapeutic hypothermia; targeted temperature management

资金

  1. AstraZeneca
  2. Bristol-Myers Squibb
  3. Daiichi-Sankyo
  4. GlaxoSmithKline
  5. Johnson and Johnson
  6. Bayer Healthcare
  7. Gilead
  8. Eisai
  9. Merck
  10. Arena
  11. Biogen Idec
  12. Boehringer Ingelheim
  13. Boston Clinical Research Institute
  14. Covance
  15. Elsevier Practice Update Cardiology
  16. Forest Pharmaceuticals
  17. GE Healthcare
  18. Lexicon
  19. St. Jude's Medical
  20. University of Calgary

向作者/读者索取更多资源

Therapeutic hypothermia for patients who remain comatose following resuscitation from a cardiac arrest improves both survival and neurologic outcomes. Although this therapy has been incorporated into the guidelines for routine post-resuscitation care and has been in clinical use for over a decade, significant questions and controversies remain. In this review, we discuss these questions in the context of the current evidence and provide a practical framework to help guide clinicians.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据